靶向Igβ的CAR-T细胞用于B细胞淋巴瘤免疫治疗
该研究构建了含CD28共刺激信号的抗Igβ CAR-T细胞,在体外及两种淋巴瘤异种移植模型中均能有效识别并清除Igβ阳性淋巴瘤细胞,其体内外效果与CD19 CAR-T相当,并可识别清除患者来源淋巴瘤细胞,引入可诱导caspase-9自杀基因系统可进一步增强安全性。
要点
- Igβ在淋巴瘤细胞表面高表达,可作为CAR-T治疗B细胞淋巴瘤的替代靶点。
- Igβ-CAR T细胞体外和体内抗淋巴瘤效果与CD19 CAR-T细胞相当。
- 引入可诱导caspase-9自杀基因系统可增强抗Igβ CAR-T细胞的安全性。
核心结论
- Igβ特异性CAR-T细胞可能是治疗B细胞淋巴瘤有前景的免疫治疗手段。
研究设计与样本
- 研究构建表达抗Igβ CAR(含CD28共刺激信号)的T细胞,在体外及两种淋巴瘤异种移植模型中评价其作用,并以野生型或突变型Igβ基因转导及靶细胞Igβ特异性敲除验证特异性。
主要发现
- Igβ-CAR T细胞在体外和两种淋巴瘤异种移植模型中均能有效识别并清除Igβ阳性淋巴瘤细胞。
- 通过野生型或突变型Igβ基因转导联合靶细胞Igβ特异性敲除,进一步确认了Igβ-CAR T细胞的特异性。
- Igβ-CAR T细胞的体外和体内效应均与CD19 CAR-T细胞相当。
- Igβ-CAR T细胞能在自体环境下识别并清除患者来源的淋巴瘤细胞。
临床怎么用
- 对于CD19 CAR-T治疗后因抗原丢失复发的B细胞淋巴瘤患者,Igβ-CAR T细胞可能提供替代靶向治疗选择。
- 临床转化时可考虑引入可诱导caspase-9自杀基因系统以增强抗Igβ CAR-T细胞的安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19-redirected CAR-T immunotherapy has emerged as a promising strategy for treatment of B cell lymphoma, however, many patients often relapsed due to antigen loss. Therefore, it is urgently needed to explore other suitable antigens targeted by CAR-T cells to cure B cell lymphoma. Igβ is a component of the B cell receptor (BCR) complex, which is highly expressed on the surface of lymphoma cells. In this study, we engineered T cells to express anti-Igβ CAR with CD28 costimulatory signaling moiety and observed that Igβ-CAR T cells could efficiently recognize and eliminate Igβ+ lymphoma cells both in vitro and in two different lymphoma xenograft models. The specificity of Igβ-CAR T cells was further confirmed through wild type or mutated Igβ gene transduction together with Igβ-specific knockout in target cells. Of note, both the in vitro and in vivo effect of Igβ CAR-T cells was comparable with that of CD19 CAR-T cells. Importantly, Igβ CAR-T cells recognized and eradicated patient-derived lymphoma cells in the autologous setting. Lastly, the safety of anti-Igβ CAR-T cells could be further enhanced by introduction of the inducible caspase-9 suicide gene system. Collectively, Igβ-specific CAR-T cells may be a promising immunotherapeutic approach for B cell lymphoma.
引用
- Jiang D, Tian X, Bian X, et al. T cells redirected against Igβ for the immunotherapy of B cell lymphoma. Leukemia. 2019. PMID: 31624374. doi:10.1038/s41375-019-0607-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。